Stocks
Funds
Screener
Sectors
Watchlists
HZNP

HZNP - Horizon Therapeutics Plc Stock Price, Fair Value and News

$116.300.00 (0.00%)
Market Closed

HZNP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HZNP Price Action

HZNP RSI Chart

HZNP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HZNP Valuation

HZNP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HZNP Fundamentals

HZNP Revenue

HZNP Earnings

HZNP Profitability

HZNP Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.6B3.6B00
20223.8B3.8B3.7B3.6B
20212.2B2.6B3.0B3.2B
20201.4B1.5B1.8B2.2B
20191.3B1.3B1.3B1.3B
20181.1B1.1B1.1B1.2B
2017997.3M1.0B1.1B1.1B
2016848.6M933.1M915.3M981.1M
2015358.2M464.9M616.3M757.0M
2014117.2M172.2M223.2M297.0M
201324.6M31.2M48.0M74.0M
20128.1M11.3M18.4M18.8M
20113.5M4.7M5.8M6.9M
20100002.4M
HZNP
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEhorizontherapeutics.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers General
 EMPLOYEES2190